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Abstract The e¡ects of nicotinamide-adenine dinucleotides
(NADH, NAD+, NADPH) on ryanodine receptor channels
(RyRs) from cardiac and skeletal muscle were compared in
planar bilayers. NADH decreased cardiac RyR activity, which
was counteracted by NAD+. In contrast, NADH and NAD+
both activated skeletal RyRs. NADPH/NADP+ were without
e¡ect on cardiac and skeletal RyRs. In the presence of ATP,
NADH inhibition of cardiac RyRs remained. Di¡erently, in the
presence of ATP both NADH and NAD+ were ine¡ective as
skeletal RyR agonists, suggesting interactions with the ATP
binding site(s) of the channels. The results suggest that the
direct e¡ect of cytosolic NADH is physiologically important
for the modulation of cardiac RyRs.
' 2003 Published by Elsevier Science B.V. on behalf of the
Federation of European Biochemical Societies.
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1. Introduction
Muscle contraction during excitation^contraction (EC) cou-
pling is triggered by intracellular Ca2þ release from sarcoplas-
mic reticulum (SR) Ca2þ stores, which is mediated by the
activation of Ca2þ release channels or ryanodine receptors
(RyRs). In mammalian muscles, three isoforms of RyRs
have been identi¢ed. The RyR1 isoform is dominant in skel-
etal muscles, whereas RyR2 represents V99% of cardiac
RyRs. The RyR3 isoform is found only at low levels in
some skeletal muscles [1,2]. The gating properties of RyRs
are controlled by a variety of cytosolic factors, which suggests
a complex regulation of these channels [1,2].
Among those factors the cytosolic redox potential seems to
play a role in RyR modulation [1^7]. The NADH/NADþ
levels are one of the important factors that control the redox
state of the cytosol. Certain metabolic conditions can signi¢-
cantly alter NADH/NADþ levels. For example, the cytosolic
NADH accumulation in ischemic myocardium results from
impairment of mitochondrial substrate shuttle systems and
from a decreased rate of cytosolic metabolism associated
with increased levels of intracellular lactate [8]. It is accepted
that ischemia leads to impairment of EC coupling and to the
generation of spontaneous SR Ca2þ oscillations [9], indicative
that a change in RyR function may be involved. It was found
that two key enzymes for the regulation of cytosolic NADH/
NADþ levels (glyceraldehyde 3-phosphate dehydrogenase,
GAPDH, and lactate dehydrogenase, LDH) are associated
with SR membranes [10,11]. Changes in activity of these en-
zymes may lead to signi¢cant changes of local NADH/NADþ
levels in close proximity to RyRs, which could a¡ect the func-
tion of these channels. There is indeed some evidence that
NADH and NADþ may modulate RyRs [12^14].
The aim of the present study was to investigate a possible
role of the cytosolic NADH/NADþ levels for the modulation
of SR Ca2þ release. We have determined the e¡ects of NADH
and NADþ on cardiac and skeletal muscle RyR channels in-
corporated in lipid bilayer. Our results suggest a novel direct
e¡ect of cytosolic NADH which is physiologically important
for the modulation of cardiac RyRs.
2. Materials and methods
All chemicals were obtained from Sigma (St. Louis, MO, USA)
unless otherwise speci¢ed. Rat ventricular and rabbit skeletal muscle
SR vesicles were obtained as described previously [15,16]. Planar lipid
bilayers were formed from a lipid mixture (Avanti Polar Lipids,
Alabaster, AL, USA) containing phosphatidylethanolamine, phospha-
tidylserine and phosphatidylcholine (ratio 5:4:1) which was dissolved
in n-decane to a ¢nal lipid concentration of 45 mg/ml. SR vesicles
were added to the cis-chamber, which corresponded to the cytosolic
side of the RyR channel. The trans-chamber (luminal side of RyR)
was connected to the virtual ground of the ampli¢er.
Fusion of SR vesicles and RyR incorporation into bilayers was
induced with the cis- and trans-chambers containing solutions of the
following composition (in mM): CsCH3SO3 400 (cis) and 40 (trans) ;
CaCl2 0.1; HEPES 20; pH 7.2 (CsOH). After channel incorporation,
trans[CsCH3SO3] was increased to 400 mM. Free [Ca2þ] in the cis-
chamber was reduced to various levels by addition of EGTA. Free
[Ca2þ] in the experimental solutions was veri¢ed with a Ca2þ-sensitive
mini-electrode [17]. Concentrations of compounds used in this study
did not change the free [Ca2þ] in the experimental solution. Single
channel currents were recorded using an Axopatch 200B ampli¢er
(Axon Instruments, Foster City, CA, USA). All recordings were
made at a holding potential of 320 mV. Currents were ¢ltered at
1 kHz and digitized at 5 kHz. Experiments were carried out at
room temperature (22^24‡C). The mean open probabilities (Po) of
the channels were used as an index of activity. Po values were calcu-
lated from the 50% threshold analysis. In multiple channel experi-
ments, the global open probability of all channels (nPo) was calcu-
lated. For simplest comparison with single channel experiments, we
show nPo/x values, where x represents the number of current levels
observed. Data are presented as meanHS.E.M. of n bilayers. Statis-
tical comparisons between groups were performed with Student’s
t-test. P9 0.05 was considered statistically signi¢cant.
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3. Results
We studied the e¡ects of NADH and NADþ on the activity
of cardiac RyRs incorporated into planar lipid bilayers. Fig.
1A illustrates the inhibitory e¡ects of NADH (0.5 and 2 mM;
added to the cytosolic side of the channel) on cardiac RyR
channel currents and Po. For cardiac RyRs in 3 WM cis[Ca2þ],
Po decreased from 0.123H 0.018 (n=8) under control condi-
tions to 0.089H 0.024 (n=8) in the presence of 0.5 mM
NADH (inhibition of 29H 10%, P6 0.05). At 2 mM NADH,
Po decreased to 0.019H 0.008 (inhibition of 84H 7%, n=8,
P6 0.002). NADH added to the luminal side did not produce
any signi¢cant e¡ect on RyR2 channel activity (data not
shown). Single channel current amplitudes remained constant
during the time of the experiment indicating no e¡ects on the
properties of channel conduction.
The activity of cardiac RyRs increased when NADþ (the
oxidized form of NADH) was added to the cytosolic side of
the channels (Fig. 1B). Po increased from 0.108H 0.024 (n=7)
under control conditions (cis[Ca2þ] 3 WM) to 0.142H 0.028
(n=7) in the presence of 2 mM NADþ (activation by
32H 9%, P6 0.05). By raising NADþ to 4 mM, Po increased
further to 0.219H 0.024 (n=7), i.e. re£ecting an activation by
107H 20% (n=7, P6 0.05). Again, luminal NADþ was with-
out e¡ect on Po. Furthermore, NADþ (luminal or cytosolic
application) did not a¡ect the conductive properties of the
cardiac RyR2.
The ¢nding that NADH and NADþ, compounds with a
similar chemical structure, produced opposite e¡ects on car-
diac RyR channels prompted us to test whether the inhibitory
e¡ects of NADH can be restored by NADþ. As illustrated in
Fig. 1C, inhibition of cardiac RyRs by NADH (2 mM, cyto-
solic side) was indeed counteracted by subsequent addition of
NADþ (2 mM). In the presence of NADH, NADþ (2 mM)
increased the Po from 0.009H 0.004 to 0.092H 0.026 (n=4),
which was not signi¢cantly di¡erent from control level
(0.114H 0.027, n=4). This e¡ect of NADþ did not appear
to be related to an independent stimulation of the channel
activity, because in control condition NADþ (2 mM) had a
signi¢cantly smaller e¡ect on the RyRs.
Fig. 1. E¡ects of NADH and NADþ on cardiac RyRs incorporated into planar lipid bilayers. A: (Left) RyR currents in control condition and
in the presence of 0.5 and 2 mM NADH. (Right) Po of cardiac RyRs vs. [NADH]. B: (Left) Cardiac RyR currents in control condition and
after addition of 2 and 4 mM NADþ. (Right) Po of cardiac RyRs vs. [NADþ]. C: (Left) Cardiac RyR currents in control condition, after ad-
dition of 2 mM NADH and subsequent addition of 2 mM NADþ. (Right) Po changes produced by NADH and by subsequent addition of
NADþ. All recordings were made at a holding potential of 320 mV and in the presence of 3 WM cis[Ca2þ]. The dotted line indicated the open
channel level. *Statistically di¡erent at P6 0.05 and **statistically di¡erent at P6 0.002.
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The cytosolic redox agent NADPH was also tested. We
found that NADPH did not inhibit cardiac RyR activity. In
four experiments Po of RyRs (cis[Ca2þ] = 3 WM) was
0.126H 0.024 in control conditions and 0.161H 0.032 in
2 mM NADPH (n=4). Furthermore, NADPH did not inter-
fere with the inhibitory e¡ects of NADH (results not shown).
Since SR Ca2þ release channels in heart and skeletal muscle
appear to be subject to di¡erent modes of regulation and
modulation [1,2], we also tested NADH and NADþ e¡ects
on skeletal RyR channels (Fig. 2). At variance with cardiac
channels (Fig. 1), we found that both NADH (Fig. 2A) and
NADþ (Fig. 2B) activated skeletal RyRs. As shown in Fig.
2A for skeletal RyRs (cis[Ca2þ] = 0.6 WM), 0.1 mM NADH
activated the channels. With 0.1 mM NADH Po increased by
142H 47% (n=5, P6 0.05). Maximal e¡ects were observed
with 2 mM NADH, where Po increased from 0.011H 0.005
(control, n=5) to 0.119H 0.023 (n=5), which corresponds to
an activation by 1015H 182% (n=5, P6 0.002). The EC50
value for RyR channel activation by NADH was 0.23 mM.
Similar to NADH, NADþ also increased the activity of
skeletal RyR channels (Fig. 2B). The EC50 value for NADþ
was 0.31 mM and the maximal e¡ect was reached at 2 mM
NADþ. Po increased from 0.012H 0.007 (n=4) under control
conditions to 0.116H 0.024 (n=4), re£ecting an activation by
893H 172% (n=4, P6 0.05).
Thus, NADH and NADþ had similar e¡ects on skeletal
Fig. 2. E¡ects of NADH and NADþ on skeletal RyR incorporated into planar lipid bilayers. A: (Left) RyR currents in control condition and
in the presence of 0.2 and 2 mM NADH. (Right) Po of skeletal RyRs vs. [NADH]. B: (Left) Skeletal RyR currents in control condition and
after addition of 0.2 and 2 mM NADþ. (Right) Po of skeletal RyRs vs. [NADþ]. C: (Left) Skeletal RyR currents in control condition, after
addition of 2 mM NADH and subsequent addition of 2 mM NADþ. (Right) Changes of Po produced by NADH and by subsequent addition
of NADþ. All recordings were made at a holding potential of 320 mV and in the presence of 0.6 WM cis[Ca2þ]. The dotted line indicates the
open channel level. *Statistically di¡erent at P6 0.05 and **statistically di¡erent at P6 0.002.
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muscle RyRs. As expected for molecules interacting with the
same binding site, we found that these compounds did not
potentiate each other (Fig. 2C). As illustrated in Fig. 2C,
NADH (2 mM) increased Po of RyRs by 843H 96% (n=3).
Subsequent addition of NADþ (2 mM) did not produce a
signi¢cant further increase in Po (914H 117%, n=3) of the
skeletal RyR channels. Vice versa, the Po of the channels
activated by NADþ (2 mM) did not signi¢cantly change by
addition of NADH (2 mM; data not shown).
Similar to cardiac RyRs, we found that NADPH had little
or no e¡ect on the activity of skeletal RyRs and did not
compete with the activating e¡ects of NADþ and NADH.
There is similarity in structure between NADþ (or NADH)
and ATP, which is an activator of RyRs [12,13]. It is then
possible that the e¡ects observed with cardiac and skeletal
RyR channels are generated, at least in part, by a distinct
interaction of NADþ and NADH with the adenine nucleotide
binding site(s). If the inhibition of cardiac RyRs by NADH
were related to these sites, then ATP (more selective agonist)
would partially diminish the NADH/NADþ e¡ects. As shown
in Fig. 3A we found that ATP (2 mM) signi¢cantly activated
cardiac RyRs. Po increased from 0.098H 0.013 to 0.793H
0.068 (n=3). Nevertheless, NADH (2 mM) markedly de-
creased Po values to 0.165H 0.037 (n=3), which represents
an inhibition of 80H 11% (Fig. 3A). This level of inhibition
of RyR activity by NADH in ATP-containing solutions was
not signi¢cantly di¡erent from that observed without ATP
(see above). Thus, inhibition of the cardiac RyR channel by
NADH may involve sites di¡erent from adenine nucleotide
binding sites of RyRs. Interestingly, for cardiac RyRs exposed
to ATP (2 mM), which elevated Po to 0.813H 0.059 (n=3),
the subsequent addition of NADþ (2 mM) did not further
increase channel activity (Po was 0.719H 0.067, n=3). These
data, on the other hand, indicate that NADþ e¡ects may be
related to an agonistic e¡ect on adenine nucleotide binding
sites.
Skeletal RyRs display a higher sensitivity to ATP [1,2].
Thus, 2 mM ATP would have maximal e¡ects on the ATP
binding sites. As expected for a compound a¡ecting nucleo-
tide binding sites, we found that both NADH and NADþ are
without e¡ects on the activity of skeletal RyRs incubated with
2 mM ATP. Fig. 3B shows that ATP (2 mM) increased Po
from 0.021H 0.008 to 0.891H 0.079 (n=3). For these almost
fully activated skeletal RyR channels, the subsequent addition
of NADH (2 mM) did not signi¢cantly change the channel
activity (Po was 0.682H 0.092, n=3). As shown on the right of
Fig. 3B, NADþ had similar e¡ects. These data indicate that
the e¡ects of NADþ and NADH on skeletal RyRs may be
related to partial agonistic e¡ects on the adenine nucleotide
binding sites that are competed by ATP.
4. Discussion
Our results show that cytosolic NADH has di¡erential di-
rect e¡ects on cardiac and skeletal RyRs. NADH inhibited
cardiac RyR channels and activated skeletal RyRs. Di¡er-
ently, NADþ had activating e¡ects on both cardiac and skel-
etal RyRs. Our results also suggest that only direct inhibition
of cardiac RyRs by NADH may have physiological relevance
as it remained in the presence of the physiological agonist
ATP. Di¡erently, the activating e¡ects of NADH and
NADþ on skeletal RyRs may just represent interactions
with nucleotide binding sites and these e¡ects would be e¡ec-
tively competed by physiological levels of ATP.
Fig. 3. E¡ects of NADH and NADþ on cardiac and skeletal RyRs activated by ATP. A: (Left) Cardiac RyR currents in control condition
(3 WM cis[Ca2þ]), in the presence of 2 mM ATP and subsequent addition of 2 mM NADH. (Right) Changes in Po of cardiac RyRs induced
by addition of ATP and by subsequent addition of NADH (¢lled symbols) or NADþ (open symbols). B: (Left) Skeletal RyR currents in con-
trol condition (0.3 WM cis[Ca2þ]), in the presence of 2 mM ATP and subsequent addition of 2 mM NADH. (Right) Changes of Po produced
by ATP and by subsequent addition of NADH (¢lled symbols) or NADþ (open symbols). All recordings were made at a holding potential of
320 mV. The dotted line indicated the open channel level. **Statistically di¡erent at P6 0.002 compared with ATP alone.
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There is evidence in the literature that NADH and NADþ
may a¡ect cardiac and skeletal RyR nucleotide binding sites
[12^14]. This is the ¢rst report, however, on the inhibitory
e¡ect of NADH on cardiac RyRs that appears to involve sites
that are not competed by ATP. For skeletal muscle it was
reported that RyR1 has an oxidoreductase-like domain that
could function as a redox sensor [14]. Our results from skel-
etal RyRs, however, suggest that the changes of the cytosolic
NADH/NADþ levels would have little or no e¡ect on the
channel when ATP is present. Yet, NADH may bind to sim-
ilar sites on the cardiac RyR that would a¡ect channel func-
tion. Since we utilized RyR channels from native membranes,
the observed inhibitory NADH e¡ect may result from a direct
interaction of NADH with cardiac RyRs or it could be medi-
ated through ancillary SR proteins that are incorporated into
the bilayers together with the RyR channels. Thus, the exact
site of the inhibitory NADH action remains to be determined.
We also found that these inhibitory sites are relatively
speci¢c for NADH. Interestingly, a similar agent such as
NADPH, which is responsible for generating redox potentials
directly in the cytosol, did not a¡ect channel activity or com-
pete with the NADH e¡ects. The only structural di¡erence
between NADH and NADPH is that the latter compound
has a phosphate group esteri¢ed to the 2-position of the ribose,
which would suggest that this group might impede the inter-
action with both inhibitory and activating sites on the RyR.
In heart, NADH levels may vary according with levels of
hypoxia or lactate accumulation [8]. For this tissue, which
usually works in a constant aerobic environment, changes of
NADH levels may be indicative of ischemic or hypoxic stress.
From our data it is apparent that NADH accumulation
would directly a¡ect the modulation of cardiac RyRs, result-
ing in an inhibition of SR Ca2þ release. In contrast, this
NADH e¡ect was absent for skeletal RyR channels. Accord-
ingly, skeletal muscle can physiologically work under various
levels of oxygenation and contains ¢bers (fast twitch muscle)
which depend mainly on anaerobic glycolysis. Therefore, they
experience changing levels of NADH [18] under physiological
conditions.
The results presented here do not negate the importance of
redox processes for the modulation of skeletal RyR activity.
Our experiments utilized an in vitro system where many or-
ganelles and cytosolic factors are absent. In cells, changes in
NADH levels may have a number of ‘indirect e¡ects’ that
could a¡ect RyR channels. For example, a recent report pro-
vides evidence that skeletal muscle SR contains an NADH-
dependent oxidase that generates superoxide (O32 .), which in
turn stimulates RyRs [19]. Additional mechanisms of cytosolic
redox modulation of cardiac and skeletal RyRs exist. There is
evidence that various oxidants and reducing agents impact
single RyR channel function [3^7], and binding of the RyR
regulatory protein calmodulin [20]. It is also known that nitric
oxide (NO) may modulate RyR channels via S-nitrosylation
of cysteine residues [21,22].
It becomes increasingly clear that redox modulation of sin-
gle RyR channels may represent a quite complex mechanism.
Nonetheless, our results suggest a novel mechanism of direct
regulation of cardiac RyR function by cytosolic NADH lev-
els.
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